相关实验视频

Updated: Sep 3, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

在贝宁市的三重阴性乳腺癌病例中,编程细胞死亡干1 (PD-L1) 表达

D O Owolabi¹, I Obahiagbon¹, M O Udoh¹

¹Department of Morbid Anatomy, University of Benin, Benin City, Nigeria. E-mail: doubra.owolabi@uniben.edu, Phone number: +234 (803) 626-5424.

West African journal of medicine

|July 6, 2025

概括

编程细胞死亡配体1 (PD-L1) 表达发生在尼日利亚贝宁市14.1%的三阴性乳腺癌 (TNBC) 中. 这一发现表明,一小部分TNBC患者可能受益于免疫检查点抑制剂治疗.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

由于缺乏细胞受体,三阴性乳腺癌 (TNBC) 缺乏向疗法.
编程细胞死亡1/编程细胞死亡联体1 (PD-1/PD-L1) 途径是癌症免疫治疗的关键标,特别是在TNBC中.

研究的目的:

在尼日利亚贝宁市的三阴性乳腺癌病例中研究PD-L1的表达模式.
评估PD-L1表达作为免疫治疗生物标志物的潜力.

主要方法:

固定在甲,嵌入的TNBC组织块的回顾性分析.
在瘤细胞上检测PD-L1表达的免疫组织化学染色.

主要成果:

在92例TNBC病例中,PD-L1表达被检测到14.1%.
在PD-L1阳性病例中的30.8%观察到扩散瘤PD-L1染色.
PD-L1表达与年龄增加显著相关,直到第五个十年 (p=0.030).

结论:

在尼日利亚南部的TNBC病例中,PD-L1表达率较低.
在这个队列中,大约14.1%的TNBC患者可能是免疫检查点抑制剂治疗的候选人.
建议进行进一步的PD-L1测试,并考虑针对已显示的TNBC病例进行免疫治疗.

关键词:

乳腺癌是什么乳腺癌免疫检查站检查站这是一种PD-L1抑制剂.三阴性乳腺癌是三阴性乳腺癌.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...